Loading...
Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients.
McGurgan, Iain J McGuigan, Christopher
McGurgan, Iain J
McGuigan, Christopher
Advisors
Editors
Other Contributors
Departments
Date
2015-10
Date Submitted
Keywords
SKIN CANCER
MYASTHENIA GRAVIS
MYASTHENIA GRAVIS
Other Subjects
Subject Mesh
Adult
Aged
Aged, 80 and over
Azathioprine
Counseling
Female
Humans
Immunosuppressive Agents
Incidence
Information Dissemination
Male
Middle Aged
Myasthenia Gravis
Patient Medication Knowledge
Risk Factors
Skin Neoplasms
Young Adult
Aged
Aged, 80 and over
Azathioprine
Counseling
Female
Humans
Immunosuppressive Agents
Incidence
Information Dissemination
Male
Middle Aged
Myasthenia Gravis
Patient Medication Knowledge
Risk Factors
Skin Neoplasms
Young Adult
Planned Date
Start Date
Collaborators
Principal Investigators
Files
Loading...
OA Article
Adobe PDF, 60.5 KB
Alternative Titles
Publisher
Abstract
Increased rates of NMSC (nonmelanoma skin cancer) have recently been reported in people with MG (myasthenia gravis) receiving azathioprine treatment. Guidelines on azathioprine for patients with dermatological and gastrointestinal disorders stress the importance of NMSC risk awareness and prevention. The aim of this study is to assess whether MG patients are being informed of this risk.
Language
en
ISSN
2162-3279
eISSN
ISBN
DOI
10.1002/brb3.396
PMID
26516615